The Drug Controller General of India has requested the withdrawal of AstraZeneca's Olaparib tablets for certain cancer treatments due to potential adverse effects.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GbwPKdE
via IFTTT
-
Vaccine manufacturer Serum Institute of India (SSI) has filed a challenge to the Supreme Court against a 2016 amendment to the Income Tax Ac...
-
Kotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient...
-
Acquista ********, Ossicodone, Ketamina, Ozempic (WhatsApp: +31616337954) I nostri prodotti hanno una purezza del 98-99%. E-mail di cont...
Search This Blog
Powered by Blogger.
Blog Archive
-
▼
2024
(774)
-
▼
May
(75)
- Aurobindo Pharma signs pact with MSD to supply bio...
- Tata Capital Healthcare Fund invests $20 million i...
- Shedding light on weight loss struggles among diab...
- Anti-diabetic drugs lead growth in pharmaceuticals...
- India's pharma export sales to grow faster this year
- Pharma bosses told to submit affidavits on ethical...
- Emergence & Application of Generative AI in Insurance
- Delhi hospital fire: How unchecked private nursing...
- Fortis lines up Rs 1,300 cr capex to expand existi...
- Panel to examine if nutraceuticals can be produced...
- Chinese scientists develop cure for diabetes, insu...
- Dr Reddy's, Cipla, Sun Pharma & others to see FY25...
- Aster to invest Rs 250 crore in CMI Hospital, to u...
- Don’t pop that pill daily: Doctors red-flag proton...
- New plant of Sun Pharma inaugurated in Bangladesh
- Sun Pharma to pursue M&A, licensing to expand spec...
- Biocon inks licensing, supply pact with South Kore...
- Local pharma companies queue up for JB Chemicals &...
- Epidural during labour associated with 35% reduced...
- Max Healthcare to widen reach via acquisitions, sa...
- Emcure and its subsidiary Gennova settle legal dis...
- DCGI orders withdrawal of cancer drug Olaparib for...
- Strides Pharma unit gets USFDA nod for generic dru...
- Cipla gets USFDA nod to market Lanreotide injection
- Regulator asks state bodies to limit scope of key...
- Alvotech, Dr. Reddy's ink pact for commercialisati...
- KKR invests in Healthcare Revenue Solutions provid...
- JB Pharma expects India business to grow above mar...
- ICMR distances itself from BHU's Covaxin study
- KKR in talks to buy into healthcare BPO company In...
- Weight loss comparison: Stairs vs strolls – which ...
- 6 compelling reasons to feast on lychees this summer
- Dr Reddy's, Sun Pharma, Aurobindo recall products ...
- Wegovy should be treating more than just obesity
- India's drug regulator cracks down on antibiotic m...
- Serum Institute buys 20% stake in US-based Integri...
- Alembic Pharma plans to launch 25 drugs in US gene...
- AstraZeneca's COVID prevention drug meets primary ...
- Covaxin side effects: What are the symptoms report...
- Study on Covaxin reports adverse events in some pa...
- Adverse events seen in some participants who took ...
- Do you work night shifts? Here's what you need to ...
- Founder Sachdev to retain majority stake in Centre...
- Derma products market seeing strong growth
- Manipal Hospitals announces brand integration of A...
- Empowering healthcare innovations: Dr. Noura Khami...
- Kotak Alt to invest Rs 400 crore in medical device...
- Biocon inks supply, distribution pact with Medix f...
- Drug regulator forms panel to evaluate OTC candidates
- Good shot, bad shot: What you need to know about C...
- Heatwave ignites surge in chronic therapy demand
- Zydus Lifesciences gets USFDA approval for generic...
- Worrying vaccination gaps come to notice after pos...
- Covishield deaths could be more than estimates: Pa...
- Serum Institute of India says it stopped manufactu...
- USFDA issues Form 483 with 1 inspectional observat...
- India reverses old trend in medical consumables bu...
- 'Govt and industry should work together to reduce ...
- Paras Healthcare Private Limited performed Bhumi P...
- New all-in-one vaccine may prove effective against...
- Serum Institute of India challenges tax amendment ...
- Quadria Capital picks up stake in NephroPlus for $...
- What is new Covid variant FLiRT, is it dangerous, ...
- As high-tech era tips the scale in favour of newer...
- Every vaccine carries a risk. If benefits outweigh...
- The penicillin war: India's journey from self-suff...
- KKR to buy Healthium Medtech for Rs 7000 cr from Apax
- Regulator revokes state licensors' power to issue ...
- Dr Reddy's launches generic anti-bacterial drug in US
- Covishield maker AstraZeneca, SII, govt all respon...
- Quadria cap picks up minority stake in NephroPlus
- Bayer acquires remaining 25% stake in Bayer Zydus ...
- Maiva Pharma raises Rs 1,000 cr from Morgan Stanle...
- Maiva Pharma raises Rs 1000 crore from Morgan Stan...
- Took AstraZeneca's Covishield? Should I be worried...
-
▼
May
(75)
Recent Posts
Unordered List
Theme Support
-
Text Widget
Design by FlexiThemes | Blogger Theme by Lasantha - PremiumBloggerTemplates.com | Best Gadgets | Distributed By Gooyaabi Templates
0 comments:
Post a Comment